Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
0 o' U) P! i5 [; C0 i( A8 {0 y7 _2 ^6 I& B5 I
' m- p& N3 T" C
Sub-category:. g* r# P+ j5 Y e
Molecular Targets & w/ `/ r7 l0 T, p* z; d8 u
- s' z) G' k" P: l/ S1 ~$ Z- P
+ P9 u, n, k9 s! Y+ b( aCategory:
2 j* |3 y( H6 u6 rTumor Biology
. Z" P& C+ ~& |% z4 R$ k7 U( @+ h A. W% T. R* O6 Q. z5 U+ T
1 |" \+ `; I& d. o6 d Z" KMeeting:
7 ^5 z# g4 p# |+ r" C2011 ASCO Annual Meeting
+ i* d2 G* k. I' o8 k0 w' ]5 _" h; K* t% T% O
, I6 Y+ C( A! d
Session Type and Session Title: N- Z6 @9 O& o
Poster Discussion Session, Tumor Biology ) _- C6 Q0 X. {1 f7 t
! U3 _# D# W8 G" b0 h1 I- p( Y0 v/ g( x; d+ ~
Abstract No:
/ {, E" |" B+ t7 ~4 L1 @10517 / w7 G8 i# y: }8 A* ^+ @2 N
$ V$ v; x* m: m- W
' j1 M+ V% \: y0 Q- MCitation:9 _, H& q- q. D1 s: j/ o
J Clin Oncol 29: 2011 (suppl; abstr 10517) ' Z3 r) Q$ ^4 k8 n: n- |. A
& L Y- T% l8 W( H6 R
6 n( u2 d# H* ]* R4 `Author(s):
- u4 E9 N$ |7 h9 a* x% zJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 _* \5 u& V; p! M# p
! _( T2 p$ U: N3 s2 c
# F9 y9 ~7 c9 {! V+ y8 g" W6 X- b/ G) H9 ?
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
) I7 u( U( `9 s7 K1 M# q4 V
1 u% i A5 Z% }6 |& D- d# [Abstract Disclosures
2 U; [& Y8 [- i% a% _. n' g a. X) D' k( E& H
Abstract:9 k |" J8 @! I+ l- A
) `8 b1 Y8 c" b2 L# a" y2 _8 }# K, Y/ H
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
% {! B! B. _4 m+ s4 r& u; ?7 w; A- S# [1 L$ B0 h- ^- }/ y
/ K+ E! n3 ]- L2 ~9 t$ K |
! r/ T" e% r7 i" |8 \
显身卡
